title: Effect of nicardipine versus enalapril on plasma endothelin-1 in hypertensive patients with type 2 diabetes mellitus.
abstract: We compared the effects of dihydropyridine type Ca channel blocker slow-release nicardipine and angiotensin converting enzyme inhibitor enalapril on plasma endothelin-1 (ET-1) levels in hypertensive type 2 diabetic patients (n=20). Nicardipine or enalapril was administered for 6 months by a crossover design. Nicardipine and enalapril comparably lowered blood pressure. Enalapril significantly reduced urinary albumin excretion in microalbuminuric patients, whereas nicardipine did not. Urinary beta2-microglobulin excretion was significantly increased during nicardipine treatment. However, both drugs significantly reduced plasma ET-1 as compared with pretreatment levels, close to that in healthy control (2.9 +/- 0.3 pg/ml in control, 4.8 +/- 0.3 pg/ml before treatment, 3.2 +/- 0.3 pg/ml during nicardipine vs before treatment p<0.05, 2.9 +/- 0.4 pg/ml during enalapril vs before treatment p<0.01). The decrease in plasma ET-1 was significantly correlated with the increase in natriuresis in normoalbuminuric patients treated with enalapril ( r= -0.82, p<0.01) but not in those treated with nicardipine. Although nicardipine and enalapril had different renal effects, both drugs equally suppressed plasma ET-1 levels in hypertensive patients with type 2 diabetes.
authors.affiliation: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. iwase@intmed 2. med.kyushu-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Iwase
authors.forename: Y
authors.initials: Y
authors.lastname: Doi
authors.forename: D
authors.initials: D
authors.lastname: Goto
authors.forename: K
authors.initials: K
authors.lastname: Ichikawa
authors.forename: K
authors.initials: K
authors.lastname: Iino
authors.forename: M
authors.initials: M
authors.lastname: Yoshinari
authors.forename: M
authors.initials: M
authors.lastname: Fujishima
mesh_terms: D000419:Albuminuria / Q000652:urine; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2; D003925:Diabetic Angiopathies / Q000097:blood* / Q000188:drug therapy* / Q000652:urine; D004656:Enalapril / Q000627:therapeutic use*; D019332:Endothelin-1 / Q000097:blood*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000627:therapeutic use*; D001613:beta 2-Microglobulin / Q000652:urine
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D019332:Endothelin-1; D001613:beta 2-Microglobulin; D004656:Enalapril; D009529:Nicardipine